SLOTS-CAPITAL
Slots Capital, et af de mest populære online casinoer i verden, er nu tilgængelig for flere spillere end nogensinde før, når de for første gang lander i flere nye lande.
Det betyder, at spillere i Belgien, Rumænien, Grækenland, Danmark, Finland, Irland, Letland og Luxembourg nu kan nyde godt af den førsteklasses online casinooplevelse, som Slots Capital tilbyder.
Hvis du elsker spillemaskiner, så er Slots Capital stedet, hvor du kan vælge mellem mere end 300 spil fra kendte udviklere såsom Rival, Saucify, Dragon og Qora.
Faktisk har vi for nylig styrket vores spillemaskiner og bordspil-lobby med titler fra eftertragtede spilstudier, herunder Rival Gaming, Dragon Gaming, Saucify Gaming og Qora Gaming.
Vi vil også tilføje spillemaskiner fra Arrow's Edge i de kommende uger, men i mellemtiden kan spillere prøve de nyeste titler ved at udforske vores lobby, som inkluderer:
- Dead Beats
- Irish Wishes
- Lucky Macau
- Panda Playtime
- Sands of Space
- Twin Dragons
- Viking Victory
- Win Another Day
- Wrath of Medusa
- Yeti Hunt i3D
Slots Capital er ikke kun kendt for at være den bedste destination for spillemaskiner, vores spillere elsker også de daglige bonusser, bonusser uden indbetaling, superhurtige udbetalinger og 24/7 kundesupport.
Vi er mobilvenlige, hvilket betyder, at du kan tilgå alle vores spillemaskiner samt vores generøse bonusser, betalingsmuligheder og kundesupport fra din smartphone eller tablet.
Hos Slots Capital vil vi gerne byde nye spillere velkommen med en enorm generøs indbetalingsmatchbonus; når du indbetaler 150 kr., tilføjer vi 450 kr. til din saldo, hvilket giver dig 600 kr. at spille med totalt.
Hvis ikke det var nok, tilbyder vi også match-bonusser på dine næste tre indbetalinger, hvor du kan modtage 250 %, 300 % og 400 %!
Sharon Kane, Slots Capital , udtalte: "Vi er så begejstrede over at have lanceret Slots Capital på otte nye markeder, og for at spillere kan nyde en af de bedste online casinooplevelser på markedet.
Vi har for nylig føjet en række efterspurgte udbydere til vores allerede imponerende lobby, hvilket viser vores engagement til at tilbyde spillere det bredest-mulige udvalg af spillemaskiner at vælge imellem.
Hvis du ikke allerede har spillet hos Slots Capital, hvad venter du så på - udnyt vores gavmilde velkomsttilbud og kom og se, hvad alle taler om."
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20210611005178/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum